A new phase 2b trial, SPINOZA, will test whether obicetrapib, a cholesteryl ester transfer protein (CETP) inhibitor, slows Alzheimer disease biomarker progression in APOE-stratified, cognitively unimpaired adults.
A phase 2a crossover trial testing low-dose and high-dose levetiracetam in early Alzheimer disease did not significantly improve global cognition versus placebo.
Results from Eli Lilly's phase 2 PRESENCE-ALZ trial show the dopamine D1 receptor modulator missed its primary cognitive and functional goal in Alzheimer disease.
Phase 3 POLARIS-AD results show AR1001 benefit on CDR-SB in a prespecified monotherapy population, but not in the overall early Alzheimer disease population.
In the prespecified mild subgroup of HOPE, 40-Hz gamma sensory stimulation was associated with 56% slowing on the ADCS-ADL and 47% slowing on the CDR-SB vs sham at 12 months.
A new global phase 2 trial, TARBELA-AD, will test RG6434, Roche's investigational oral NLRP3 inflammasome inhibitor, in adults with early symptomatic Alzheimer disease.
A real-world registry found that large infarct core size does not independently predict worse functional or safety outcomes after thrombectomy, compared with moderate-core infarcts.
Angela Lek, PhD, chief research officer at the Muscular Dystrophy Association, discussed how the 2027 MDA Clinical and Scientific Conference agenda reflects key themes in neuromuscular medicine.